BioPorto A/S increases the share capital through a cash issue, private placement.
来源: Nasdaq GlobeNewswire / 27 十月 2017 02:49:54 America/New_York
Today, BioPorto A/S will initiate a private placement of up to 13,015,625 new shares to selected shareholders, institutional and financial investors. The offering of shares will be made at market price without pre-emptive rights for existing shareholders.
Today, the Board of Directors of BioPorto A/S (BioPorto) has decided to carry out a cash issue, private placement, of up to 13,015,625 new shares at market price.
Use of proceeds
In April 2017, BioPorto commenced the recruitment of 530 patients for its US clinical study to generate the data that will support the FDA application for The NGAL Test™. The recruitment is progressing per the announced plan. To prepare for a commercial US roll-out after FDA approval, support the current uptrend in sales and strengthen the company’s overall liquidity, BioPorto’s board has today decided to initiate a private placement.
The capital increase takes the form of a cash issue directed at a limited group of shareholders, institutional and financial investors without a pre-emptive right for the Company’s existing shareholders according to the authorization stipulated in Article 16b of BioPorto’s Articles of Association.
The offering comprises up to 13,015,625 new shares at DKK 1 each, equivalent to 9.13% of BioPorto’s registered share capital prior to the capital increase. The Board of Directors has received binding advance subscription commitments for the full number of the new shares. The subscription price is DKK 3.20 and is calculated as the weighted average price of the share at Nasdaq Copenhagen over the past ten trading days. The expected total proceeds from the share issue will amount to DKK 41.7 million at full subscription.
The newly subscribed shares will carry the same rights as the existing shares. The new shares shall be registered in the name of the holder through VP SECURITIES A/S. The rights relating to the new shares, including voting rights and dividend rights, will apply from the time when the capital increase is registered with the Danish Business Authority.
Expected timetable for the capital increase
The subscription period starts today and ends on November 2, 2017. The Board of Directors may choose to complete the issue prior to this date. The capital increase will be registered with the Danish Business Authority as soon as the subscription amount is fully paid, which is expected on November 3, 2017.
The new shares are expected to be admitted to trading and official listing on Nasdaq Copenhagen under the existing ISIN code for BioPorto's shares by the end of November 2017. No prospectus will be prepared in connection with the offering or the listing.
Guidance for 2017 maintained
The content of this announcement does not affect BioPorto’s latest financial guidance for 2017, which remains revenue of DKK 26-28 million and an EBIT loss in the range DKK 28-35 million.
For further information, please contact:
Peter Mørch Eriksen, CEO
Telephone +45 4529 0000, e-mail email@example.com
BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. Our pioneering product portfolio includes assays for underserved disease states such as NGAL for acute kidney injury. We sell our products in more than 80 countries through diverse sales channels and partners. BioPorto has its headquarters in Copenhagen, Denmark and is listed on the Nasdaq Copenhagen stock exchange.
This announcement contains forward-looking statements on BioPorto’s future financial developments and financial results as well as other statements that are not historical facts and that may prove to be incorrect. Prospective investors should seek professional investment advice and examine relevant risks and legal aspects, including tax aspects, which could be relevant in connection with an acquisition of the shares.
The information contained herein is not for publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. These written materials do not constitute an offer of securities for sale in any jurisdiction including the United States, nor may the securities be offered or sold in the United States absent registration or an exemption from registration as provided in the U.S. Securities Act of 1933, as amended, and the rules and regulations thereunder. There is no intention to register any portion of the offering in the United States or to conduct a public offering of securities in the United States.
The issue and sale of securities in the offering are subject to specific legal or regulatory restrictions in certain jurisdictions. BioPorto and its advisers and/or agents assume no responsibility in the event there is a violation by any person of such restrictions.
The information contained herein shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction.
This announcement is only addressed to and directed at persons in member states of the European Economic Area (the “EEA”), who are “Qualified Investors” within the meaning of Article 2(1)(e) of the Prospectus Directive. The securities are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with Qualified Investors. This announcement should not be acted upon or relied upon in any member state of the EEA by persons who are not Qualified Investors. For the purposes of this announcement, the expression “Prospectus Directive” means Directive 2003/71/EC as amended and includes any relevant implementing measure in each Relevant Member State. This announcement is an advertisement for the purposes of applicable measures implementing the Prospectus Directive.